EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY-NC-SA 4.0

HER2-low breast cancer: a new diagnostic challenge for pathologists – insights from a single-center retrospective cohort

Joanna Fuks, Aleksandra Kalinowska, Daria Osowska, Aleksandra Pręgowska-Szczęsna, Anna Maria Nasierowska-Guttmejer

Polish Journal of Pathology · 28.10.2026 · 77 (3) · 296-303

DOI: 10.5114/pjp/236246 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Polish Journal of Pathology, online erschienen am 28.10.2026. Verfasst von Joanna Fuks und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathomorphology, Lazarski University, Warsaw, Poland. Hauptthemen laut MEDLINE: Breast Neoplasms, Erb-b2 Receptor Tyrosine Kinases, Biomarkers, Tumor. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-SA 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The introduction of antibody-drug conjugates, particularly trastuzumab deruxtecan, has fundamentally changed the clinical significance of low HER2 expression in breast cancer. Consequently, accurate discrimination between human epidermal growth factor receptor 2 (HER2) immunohistochemistry (IHC) score 0 and HER2-low (IHC 1+ or IHC 2+/ISH-negative) has become increasingly important in routine pathological practice. This retrospective single-center observational study included consecutive patients diagnosed with invasive breast carcinoma between January 2023 and December 2024. Histopathological and immunohistochemical slides were re-evaluated according to current American Society of Clinical Oncology/College of American Pathologists recommendations. Cases were reclassified into HER2 0, HER2-low, and HER2-positive categories. Clinicopathological variables, including patient age, histological subtype, hormone receptor status, Ki-67 proliferation index, histological grade, and biological subtype, were analyzed using descriptive statistics. Seventy-eight patients were analysed. Following reassessment, HER2-low tumors accounted for 33.3% (26/78) of all invasive breast cancers. Fifteen tumors initially classified as HER2 0 were reclassified as HER2-low. All HER2-low tumors were invasive carcinoma of no special type. Luminal B represented the predominant molecular subtype (65.4%), followed by triple-negative breast cancer (30.8%) and luminal A tumors (3.8%). Estrogen receptor expression was observed in 69.2% of HER2-low tumors, while progesterone receptor expression was detected in 61.5%. Reclassification of HER2 expression substantially increased the number of patients classified as HER2-low, emphasizing the importance of precise immunohistochemical assessment, particularly in distinguishing IHC score 0 from IHC score 1+. These findings highlight the growing clinical relevance of standardized HER2 assessment in identifying patients who may become eligible for HER2-targeted antibody-drug conjugate therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsErb-b2 Receptor Tyrosine KinasesBiomarkers, TumorHumansFemaleRetrospective StudiesMiddle AgedImmunohistochemistryAgedAdultAged, 80 and over

Stichwörter der Autor:innen

HER2 reclassificationHER2-lowbreast cancercore needle biopsyderuxtecanimmunohistochemistrypathologypredictive biomarkerstrastuzumab

Substanzen

Erb-b2 Receptor Tyrosine KinasesBiomarkers, TumorERBB2 protein, human

Autor:innen und Institutionen

  • Department of Pathomorphology, Lazarski University, Warsaw, Poland.
  • Pathomorphology Center, National Medical Institute of the Ministry of the Interior and Administration National Medical Institute, Warsaw, Poland.

Zitieren

APA

Fuks, J., Kalinowska, A., Osowska, D., Pręgowska-Szczęsna, A., & Nasierowska-Guttmejer, A. M. (2026). HER2-low breast cancer: a new diagnostic challenge for pathologists – insights from a single-center retrospective cohort. Polish Journal of Pathology, 77(3), 296-303. https://doi.org/10.5114/pjp/236246

Vancouver

Fuks J, Kalinowska A, Osowska D, Pręgowska-Szczęsna A, Nasierowska-Guttmejer AM. HER2-low breast cancer: a new diagnostic challenge for pathologists – insights from a single-center retrospective cohort. Polish Journal of Pathology. 2026;77(3):296-303. doi:10.5114/pjp/236246

BibTeX
@article{Fuks2026,
  author = {Fuks, Joanna and Kalinowska, Aleksandra and Osowska, Daria and Pręgowska-Szczęsna, Aleksandra and Nasierowska-Guttmejer, Anna Maria},
  title = {HER2-low breast cancer: a new diagnostic challenge for pathologists – insights from a single-center retrospective cohort},
  journal = {Polish Journal of Pathology},
  year = {2026},
  volume = {77},
  number = {3},
  pages = {296--303},
  doi = {10.5114/pjp/236246}
}
Kostenlos starten →